Gut dysbiosis-driven monocyte reprogramming toward NETotic phenotype accelerates AD pathology
🧪 Overview
Intestinal barrier dysfunction and LPS translocation primes CCR2+ circulating monocytes and neutrophils toward a NETosis-prone phenotype via TLR4/NF-κB axis activation and PAD4 upregulation. These hyper-NETotic neutrophils exhibit increased CNS trafficking across the compromised blood-brain barrier in AD, depositing granzyme B and chromatin traps that directly induce synaptic damage while triggering persistent microglial activation. The resulting feed-forward loop amplifies neuroinflammation and accelerates amyloid plaque-associated pathology. Testable prediction: inhibiting PAD4 or blocking neutrophil CNS infiltration will reduce neurodegeneration markers and preserve cognitive function in 5xFAD mice colonized with dysbiotic human microbiota.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Gut Dysbiosis<br/>Microbial Signal"]
B["Monocyte<br/>Reprogramming"]
C["NETotic Phenotype<br/>Neutrophil Extracellular Traps"]
D["AD Pathology<br/>Acceleration"]
E["Neurotoxicity<br/>Neuronal Loss"]
F["MMP9 as<br/>Monocyte Reprogramming Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MMP9
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MMP9.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF neutrophil trafficking to the CNS is blocked via chronic anti-Ly6G antibody administration (αLy6G, 200 μg i.p., twice weekly for 8 weeks) in 5xFAD mice colonized with dysbiotic human microbiota, TH | ≥60% depletion of brain CD45+Ly6G+ neutrophils, ≥35% reduction in hippocampal granzyme B, ≥30% decrease in neurodegeneration biomarkers, and ≥25% improvement in | — no observation — | pending | 0.68 |
| IF pharmacological PAD4 inhibition (e.g., GSK484, 10 mg/kg, daily i.p. for 8 weeks) is administered to 5xFAD mice colonized with dysbiotic human microbiota starting at 3 months of age, THEN measurable | ≥40% reduction in brain NET markers, ≥30% decrease in MMP9 activity, ≥25% preservation of synaptic proteins, and ≥20% improvement in Morris water maze performan | — no observation — | pending | 0.72 |
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |